Moderna

In Q1 2026 the EU approves mCOMBRIAX (flu+COVID combination), mNEXSPIKE, and an expanded mRESVIA label (adults 18+). Moderna also agrees to a ~$950M settlement of the Arbutus/Genevant lipid-nanoparticle patent litigation, with payment expected in Q3 2026.

At the June 2026 ASCO meeting, Moderna and Merck present five-year Phase 2b data for intismeran autogene (mRNA-4157) plus KEYTRUDA in high-risk resected melanoma, sustaining a ~49% reduction in recurrence-or-death risk versus KEYTRUDA alone.

On June 18, 2026 an FDA advisory committee votes 9-0 that the benefits of Moderna's standalone mRNA seasonal flu vaccine (mRNA-1010) outweigh its risks in adults 50+, ahead of an August 2026 FDA decision. The vote drives a sharp stock rally.

On July 16, 2026 Moderna dosed the first U.S. participant in a Phase 1 trial of mRNA-4200, an off-the-shelf, tumor-targeted cancer antigen therapy given with checkpoint-inhibitor treatment in adults with advanced or metastatic solid tumors. The candidate — Moderna's third off-the-shelf cancer antigen therapy, developed with Immatics — encodes seven antigens commonly shared across patients and tumor types to induce and expand T-cell responses. The open-label, multicenter, dose-escalation study is evaluating safety and tolerability, extending Moderna's oncology pipeline beyond the individualized intismeran autogene program.

Next-generation, lower-dose COVID vaccine mNEXSPIKE (mRNA-1283) is approved. Facing a post-COVID revenue decline, Moderna cuts ~$2.2B of annual operating expenses and lays off ~10% of its workforce (500+ roles), targeting fewer than 5,000 employees.

The FDA approves mRESVIA (mRNA-1345) for RSV in older adults in May 2024, making it Moderna's second commercial product and the first mRNA vaccine approved for a disease other than COVID-19.

Spikevax receives full FDA approval in January 2022. COVID vaccine sales drive Moderna's revenue to a peak of more than $18B for the year.

mRNA-1273 (later Spikevax), developed with support from Operation Warp Speed (~$955M), receives FDA EUA on December 18, 2020 — Moderna's first product and the validation of mRNA vaccines at global scale.

Lists on NASDAQ under ticker MRNA in December 2018, raising ~$621M (27M shares at $23) — the largest biotech IPO to that point.

Raises $450M in one of the largest private financings in biotech history, and forms a foundational oncology collaboration with Merck that later underpins the mRNA-4157/V940 cancer vaccine.

Signs a cardiometabolic and cancer partnership with AstraZeneca ($240M upfront) and receives a $25M DARPA grant, validating the platform with major backers before any product exists.

Bancel, previously CEO of diagnostics firm bioMérieux, takes the helm and begins building Moderna's mRNA platform. He remains CEO through 2026.

Incubated by Flagship Pioneering in Cambridge, Massachusetts, around the idea of using messenger RNA to instruct cells to produce their own therapeutic proteins. Founding figures include Derrick Rossi, Robert Langer, Kenneth Chien, Timothy Springer, and Noubar Afeyan.